VLDL Cholesterol (Very Low‑Density Lipoprotein Cholesterol): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Very low‑density lipoprotein (VLDL) is one of the three major classes of lipoproteins, along with LDL and HDL. It is synthesised by the liver and serves as the primary carrier of endogenous triglycerides – triglycerides produced in the liver, as opposed to those absorbed from the diet. VLDL particles are larger and less dense than LDL, and as they circulate, they undergo lipolysis, losing triglycerides and becoming smaller, denser LDL particles.

VLDL cholesterol (VLDL‑C) is the cholesterol carried within these particles. Because VLDL particles are pro‑atherogenic – they can infiltrate the arterial wall and contribute to plaque formation – VLDL‑C is considered part of the non‑HDL cholesterol fraction (total cholesterol minus HDL). Non‑HDL cholesterol includes all atherogenic lipoproteins (VLDL, IDL, LDL, lipoprotein(a)) and is a superior cardiovascular risk marker than LDL‑C alone, particularly when triglycerides are elevated.

In clinical practice, VLDL‑C is usually not measured directly. It is most commonly estimated as triglycerides divided by 5 (or triglycerides divided by 2.2 in mmol/L), based on the assumption that VLDL particles carry approximately five times as much triglyceride as cholesterol. This estimation is reasonably accurate when triglycerides are in the normal to moderately elevated range (<400 mg/dL, 4.5 mmol/L) and the patient is fasting. Direct measurement is available but rarely necessary.

Clinical role: VLDL‑C is not a primary treatment target. Its main utility is in the calculation of LDL‑C via the Friedewald equation and in the assessment of atherogenic particle burden through non‑HDL cholesterol. Elevated VLDL‑C reflects excess hepatic triglyceride secretion and is a hallmark of insulin resistance, metabolic syndrome, and type 2 diabetes.

---

2. What does it measure

a. Units of measurement

· Milligrams per decilitre (mg/dL) – standard in the United States

· Millimoles per litre (mmol/L) – used in many other countries (divide mg/dL by 38.67)

b. Normal Range and Interpretation

(Reference ranges are laboratory‑dependent; VLDL‑C is rarely reported in isolation and is usually interpreted in the context of triglycerides and non‑HDL cholesterol.)

Fasting VLDL‑C (estimated or directly measured):

· Normal: 5–30 mg/dL (0.1–0.8 mmol/L)

· Borderline high: 30–40 mg/dL (0.8–1.0 mmol/L)

· High: greater than 40 mg/dL (>1.0 mmol/L)

Non‑HDL cholesterol (total cholesterol – HDL):

· Optimal: less than 130 mg/dL (3.4 mmol/L)

· High risk: 130–189 mg/dL (3.4–4.9 mmol/L)

· Very high risk: greater than 190 mg/dL (>4.9 mmol/L)

Interpretation notes:

· VLDL‑C is directly proportional to fasting triglyceride levels when triglycerides are <400 mg/dL:

· VLDL‑C (mg/dL) ≈ Triglycerides (mg/dL) ÷ 5

· VLDL‑C (mmol/L) ≈ Triglycerides (mmol/L) ÷ 2.2

· This estimation fails when triglycerides are ≥400 mg/dL (4.5 mmol/L); direct LDL measurement or non‑HDL cholesterol should be used.

· Non‑HDL cholesterol is a more reliable marker of total atherogenic particle burden than VLDL‑C alone and is the preferred secondary target after LDL‑C.

· Remnant cholesterol (non‑HDL cholesterol minus LDL‑C) is another emerging marker; it represents cholesterol in VLDL and IDL particles and is particularly atherogenic.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise VLDL cholesterol)

Since VLDL‑C is closely tied to triglyceride metabolism, factors that increase hepatic VLDL secretion or impair VLDL clearance will raise VLDL‑C.

Factors that increase VLDL production:

· Excess carbohydrate intake, particularly fructose and refined sugars – stimulate de novo lipogenesis, increasing hepatic triglyceride synthesis and VLDL secretion.

· Insulin resistance / type 2 diabetes – failure of insulin to suppress VLDL production; increased free fatty acid flux to liver.

· Obesity, especially visceral adiposity – increased delivery of free fatty acids to liver.

· Alcohol – enhances hepatic triglyceride synthesis.

· Genetic: familial combined hyperlipidaemia, familial hypertriglyceridaemia.

· Medications: oestrogens, glucocorticoids, isotretinoin, atypical antipsychotics, protease inhibitors.

· Pregnancy – physiological rise.

Factors that decrease VLDL clearance:

· Lipoprotein lipase (LPL) deficiency or dysfunction – genetic or acquired (insulin resistance).

· Apolipoprotein C‑II deficiency – cofactor for LPL.

· Chronic kidney disease – reduced LPL activity.

· Hypothyroidism – reduced LPL expression.

Thus, elevated VLDL‑C is associated with:

· Hypertriglyceridaemia (fasting triglycerides ≥150 mg/dL).

· Metabolic syndrome, diabetes, obesity.

· High‑carbohydrate, high‑sugar diets.

· Alcohol overuse.

· Genetic dyslipidaemias affecting triglyceride metabolism.

b. Indirect correlation (factors that influence VLDL‑C interpretation or cause artefactual changes)

· Fasting status: Essential. Non‑fasting triglycerides are significantly higher due to chylomicrons (dietary fat); VLDL‑C estimated from non‑fasting triglycerides will be falsely elevated. Always use fasting samples for triglyceride and VLDL‑C assessment.

· Recent alcohol intake: Even modest alcohol consumption within 24–48 hours elevates triglycerides and VLDL‑C; advise abstinence for 48–72 hours before testing.

· Acute illness / infection / inflammation: Triglycerides may be elevated (increased VLDL) or decreased; defer testing for 4–6 weeks.

· Pregnancy: VLDL‑C rises progressively; use non‑pregnant reference ranges only after 6 weeks postpartum.

· Medications: as above.

· Assay issues:

· When triglycerides exceed 400 mg/dL (4.5 mmol/L), the Friedewald estimation is invalid; VLDL‑C cannot be reliably calculated.

· Direct homogeneous assays for LDL‑C may also be affected; non‑HDL cholesterol is preferred.

· Genetic variants: Some individuals have naturally higher or lower VLDL production; familial patterns exist.

---

4. Disorders related to abnormal values

a. When VLDL cholesterol is elevated (hypertriglyceridaemia, increased atherogenic particles)

Moderate elevation (VLDL‑C 30–40 mg/dL; triglycerides 150–200 mg/dL):

· Metabolic syndrome.

· Type 2 diabetes (early, well‑controlled).

· Overweight / obesity.

· High‑carbohydrate diet.

· Familial combined hyperlipidaemia.

Significant elevation (VLDL‑C >40 mg/dL; triglycerides 200–499 mg/dL):

· Overt hypertriglyceridaemia.

· Poorly controlled diabetes.

· Chronic kidney disease.

· Alcohol overuse.

· Hypothyroidism.

· Familial hypertriglyceridaemia.

· Medications (oestrogens, glucocorticoids, antiretrovirals).

Severe elevation (VLDL‑C often cannot be calculated; triglycerides ≥500 mg/dL):

· Pancreatitis risk – especially when triglycerides >1000 mg/dL.

· Lipoprotein lipase deficiency, apolipoprotein C‑II deficiency.

· Familial hypertriglyceridaemia with secondary exacerbation.

· Type III hyperlipoproteinaemia (dysbetalipoproteinaemia) – VLDL remnants accumulate.

b. When VLDL cholesterol is low (usually benign)

· Malnutrition / malabsorption – coeliac disease, short bowel syndrome.

· Hyperthyroidism – increased LPL activity, enhanced clearance.

· Abetalipoproteinaemia / familial hypobetalipoproteinaemia – absence or marked reduction of VLDL.

· Advanced liver disease – reduced VLDL synthesis.

· Medications: high‑dose omega‑3, fibrates, niacin (therapeutic).

· Genetic: rare LPL gain‑of‑function variants.

Interpretation note: Isolated low VLDL‑C in an asymptomatic person is of no clinical concern.

---

5. Best way to address aberrant levels

Important principle: VLDL‑C is not a treatment target. Intervention should focus on lowering triglycerides and reducing non‑HDL cholesterol to guideline‑recommended goals. The cornerstone of management is lifestyle modification – diet, exercise, weight loss, and alcohol restriction. Pharmacotherapy is indicated for pancreatitis prevention (triglycerides ≥500 mg/dL) and for cardiovascular risk reduction in persistent hypertriglyceridaemia despite lifestyle.

a. Quick ways or using Medications

For severe hypertriglyceridaemia (≥500 mg/dL) – pancreatitis prevention:

· Fibrates:

· Fenofibrate – first‑line; lowers triglycerides by 30–50%, reduces VLDL secretion, enhances LPL activity.

· Gemfibrozil – effective but higher myopathy risk with statins; avoid combination unless necessary.

· Omega‑3 fatty acids (prescription):

· Icosapent ethyl – purified EPA ethyl ester; lowers triglycerides by 20–30%, reduces cardiovascular events in high‑risk patients with triglycerides 135–499 mg/dL on statin (REDUCE‑IT).

· Caution: Most prescription omega‑3 is fish‑derived; prefer algal EPA/DHA if available, though evidence base for cardiovascular benefit is strongest for icosapent ethyl. In severe hypertriglyceridaemia, discuss with physician; ecological considerations must be balanced against immediate pancreatitis risk.

· Statins:

· Modest triglyceride reduction (10–20%); indicated if concomitant elevated LDL or ASCVD risk.

For moderate hypertriglyceridaemia (150–499 mg/dL) – cardiovascular risk reduction:

· Statins – primary therapy if LDL is above goal; triglyceride reduction is a secondary benefit. Non‑HDL cholesterol becomes the treatment target.

· Icosapent ethyl – add‑on to statin in high‑risk patients with triglycerides 135–499 mg/dL.

· Fibrates – may be added in high‑risk patients with persistent hypertriglyceridaemia, though cardiovascular outcome benefit is modest.

For secondary causes:

· Diabetes: improve glycaemic control (metformin, SGLT2 inhibitors, GLP‑1 receptor agonists – these also modestly lower triglycerides).

· Hypothyroidism: levothyroxine replacement.

· Obesity: weight loss is most effective.

· Offending medications: discontinue or switch if possible.

Do not self‑prescribe – all prescription lipid‑modifying medications require medical supervision.

b. Using Supplements or Holistic medicine

Supplements with evidence for triglyceride / VLDL‑C lowering:

· Omega‑3 fatty acids (EPA/DHA):

· Dose‑dependent reduction in hepatic VLDL synthesis; 2–4 g/day lowers triglycerides by 20–40%.

· Preferred source: Algae oil – sustainable, plant‑based, direct EPA/DHA, no marine contaminants.

· Avoid conventional fish oil (overfishing, ocean pollution, ethical concerns).

· Form: re‑esterified triglyceride form for optimal absorption.

· Caution: May increase LDL‑C in some patients; monitor.

· Berberine:

· Reduces triglycerides by 15–25%; upregulates LDL receptor, improves insulin sensitivity.

· Preferred source: Standardised berberine (≥97%) from Berberis aristata or Phellodendron amurense.

· Dose: 500 mg twice daily.

· Caution: GI side effects, drug interactions (statins, cyclosporine, anticoagulants); avoid in pregnancy.

· Soluble fibre:

· Psyllium (10 g/day), beta‑glucans (oats, barley), glucomannan – modest triglyceride reduction (5–10%).

· Preferred sources: oat bran, psyllium husk, barley, legumes.

· Green tea extract (EGCG):

· Modest triglyceride lowering (5–10%) in meta‑analyses.

· Use beverage (2–3 cups/day) rather than concentrated extracts (hepatotoxicity risk).

· Garlic (Allium sativum):

· Aged garlic extract; small triglyceride reduction.

· Curcumin (turmeric):

· Anti‑inflammatory; some studies show modest triglyceride reduction.

· Use phytosomal, liposomal, or with piperine for bioavailability.

· Vitamin D:

· Deficiency linked to hypertriglyceridaemia; supplementation may improve lipid profile in deficient individuals.

· Preferred: D3 (cholecalciferol) from lichen.

· Magnesium:

· Deficiency associated with hypertriglyceridaemia; supplementation may modestly improve levels.

· Preferred forms: glycinate, citrate, malate.

· Chromium:

· Controversial; may improve insulin sensitivity; weak triglyceride effect.

Supplements with limited or no evidence for VLDL‑C / triglyceride lowering:

· Niacin – effective but not recommended due to side effects and lack of outcome benefit.

· Plant sterols/stanols – primarily LDL‑C lowering; minimal triglyceride effect.

· Policosanol – ineffective.

Ayurvedic approaches:

· Fenugreek (Trigonella foenum‑graecum):

· Seeds; soluble fibre content may reduce triglycerides; modest effect.

· Guggulu (Commiphora mukul):

· Standardised guggulsterones; modest lipid‑lowering, but efficacy debated and hepatotoxicity concerns.

· Arjuna (Terminalia arjuna):

· Limited evidence for lipid lowering.

· Always consult a qualified practitioner; herbs can interact with medications.

Supplements to avoid:

· Products with added synthetic folic acid or cyanocobalamin – use methylfolate and methylcobalamin if needed.

· Unregulated herbal blends with undisclosed ingredients.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

Diet is the cornerstone of VLDL‑C and triglyceride management. Reduction of 20–50% is achievable with consistent dietary modification.

Core dietary principles – what to emphasise:

· Reduce total carbohydrate intake, especially refined carbohydrates and added sugars:

· Fructose restriction is critical – eliminate sugary beverages (soft drinks, fruit juices, sweetened teas), sweets, pastries. Fructose directly drives hepatic de novo lipogenesis and VLDL production.

· Replace refined grains (white bread, white rice, pasta) with whole grains (oats, barley, quinoa, brown rice, millets).

· Limit added sugars to less than 5–10% of total energy.

· Replace saturated fats with unsaturated fats:

· Extra virgin olive oil – principal fat.

· Nuts and seeds – walnuts, almonds, flaxseeds, chia seeds, hemp seeds.

· Avocado.

· Increase omega‑3 fatty acids:

· ALA sources: ground flaxseeds, chia seeds, hemp seeds, walnuts.

· Direct EPA/DHA: microalgae (spirulina, chlorella – limited amounts); algae oil supplements for therapeutic doses.

· Increase soluble fibre:

· Oats, barley, psyllium, eggplant, okra, legumes (lentils, chickpeas, beans).

· Target ≥30 g total fibre daily, with 10–20 g soluble fibre.

· Achieve and maintain healthy weight:

· Weight loss of 5–10% reduces triglycerides and VLDL‑C by 20–30%.

· Alcohol:

· Complete abstinence if VLDL‑C or triglycerides are elevated, especially if >200 mg/dL. Even small amounts can exacerbate hepatic triglyceride synthesis.

Specific foods with evidence for VLDL‑C / triglyceride lowering:

· Oats and barley: beta‑glucan – 3 g/day.

· Legumes: lentils, chickpeas, beans – ½ cup daily.

· Nuts: 30 g/day – walnuts, almonds.

· Soy protein: tofu, tempeh, edamame – 25 g/day.

· Fatty fish alternatives: not applicable – use algae oil supplements for EPA/DHA.

· Green tea: 2–3 cups/day.

· Chilli peppers: capsaicin may modestly lower triglycerides.

· Garlic, onions: organosulfur compounds.

What to avoid or severely limit:

· Added sugars and high‑fructose corn syrup – soft drinks, fruit juices, sweets, ice cream, commercial baked goods.

· Refined carbohydrates – white bread, white rice, pasta, sugary cereals.

· Excess alcohol – zero is optimal.

· Trans fats – partially hydrogenated oils.

· Saturated fats – butter, cream, cheese, fatty meats, palm oil, coconut oil.

Protein sources (hierarchy adhered):

· Plant‑based (primary): legumes, soy products (tofu, tempeh, edamame), seitan.

· Fungi / algae (encouraged): mycoprotein (Quorn), spirulina, chlorella.

· Biotechnology / lab‑grown (acceptable): precision‑fermented dairy proteins (animal‑free whey, casein).

· Dairy / eggs (permitted but not emphasised): low‑fat fermented dairy (yoghurt, kefir) if tolerated; full‑fat dairy contains saturated fat.

· Meat, poultry, fish: deliberately omitted. Effective plant‑based alternatives exist to meet all nutritional requirements for VLDL‑C and triglyceride management. There is no need for animal products to reduce VLDL‑C or achieve normal triglyceride levels.

---

6. How soon can one expect improvement and the ideal time frame to retest

VLDL‑C and triglycerides respond rapidly – within days to weeks.

For dietary and lifestyle interventions:

· Carbohydrate / sugar restriction: VLDL‑C and triglycerides begin to fall within 3–7 days; maximal reduction (20–40%) by 4–6 weeks.

· Weight loss: 5–10% weight loss reduces VLDL‑C by 20–30% over 3–6 months.

· Alcohol abstinence: VLDL‑C declines within 3–7 days; full effect in 2–4 weeks.

· Exercise: acute bout lowers triglycerides post‑exercise; sustained training reduces fasting VLDL‑C in 4–12 weeks.

For supplements:

· Omega‑3 (algae oil): 2–4 g/day reduces triglycerides and VLDL‑C within 4–8 weeks.

· Berberine: triglyceride reduction detectable in 4–8 weeks.

· Soluble fibre: 4–8 weeks.

For medications:

· Fibrates: triglyceride / VLDL‑C reduction within 2–4 weeks; maximal effect at 6–8 weeks.

· Icosapent ethyl: 4–8 weeks.

· Statins: modest reduction at 6–8 weeks.

Retesting interval:

· Severe hypertriglyceridaemia (≥500 mg/dL): repeat fasting lipid panel in 4–8 weeks after lifestyle and/or medication initiation. If triglycerides remain ≥1000 mg/dL, immediate medical follow‑up for pancreatitis prevention.

· Moderate hypertriglyceridaemia (150–499 mg/dL): repeat in 8–12 weeks after intervention.

· At goal: annually, or more frequently if clinical status changes.

· Do not retest more often than every 4 weeks unless monitoring acute pancreatitis risk.

---

Conclusion

VLDL cholesterol is the lipid fraction that connects the liver's carbohydrate metabolism to the bloodstream's atherogenic cargo. It is not a standalone target but an integral component of non‑HDL cholesterol – the sum of all lipoproteins that injure arteries. An elevated VLDL‑C is not a diagnosis; it is a metabolic signature of excess sugar, refined starch, alcohol, visceral fat, and insulin resistance.

The treatment is not to attack VLDL directly but to correct the metabolic disturbances that drive its overproduction. Carbohydrate restriction, fructose elimination, weight loss, exercise, and alcohol abstinence are the foundational interventions. When these are insufficient – particularly when pancreatitis threatens – fibrates and omega‑3s are effective and evidence‑based.

A plant‑based, ecologically responsible diet – whole grains, legumes, nuts, seeds, and algae‑derived omega‑3s – is perfectly designed to lower VLDL‑C. It is low in saturated fat, devoid of cholesterol, rich in fibre, and free of the concentrated fructose that fuels hepatic fat synthesis. Meat is not only unnecessary; its displacement by plants is itself the therapy.

VLDL‑C is a messenger. Listen to what it says about the diet and the metabolism – then change what needs changing.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x